Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Hemangiosarcoma 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Esophagogastric Cancer 1Colonic Neoplasms 1Adenocarcinoma of the Prostate 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × STA 9090 × Clear all
NCT01562015 2015-05-20

CHIARA

Synta Pharmaceuticals Corp.

Phase 2 Completed
12 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01031225 2014-09-19

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Synta Pharmaceuticals Corp.

Phase 2 Completed
113 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡